Please login to the form below

Not currently logged in
Email:
Password:

affordability

This page shows the latest affordability news and features for those working in and with pharma, biotech and healthcare.

Spark sets Luxturna price, igniting US affordability debate

Spark sets Luxturna price, igniting US affordability debate

Spark sets Luxturna price, igniting US affordability debate. The IRD treatment is set to cost patients $425, 000 per eye.

Latest news

  • What value for innovation in an era dominated by affordability? What value for innovation in an era dominated by affordability?

    What value for innovation in an era dominated by affordability? Pharma can collaborate but must be clear about its motives. ... As health services across the globe grapple with affordability challenges and future sustainability, many are facing similar

  • NICE: We're the institute of 'yes' NICE: We're the institute of 'yes'

    NICE: We're the institute of 'yes'. But Meindert Boysen says affordability conversations with pharma need to happen earlier.

  • R&D productivity still a big problem for biopharma R&D productivity still a big problem for biopharma

    But while that level of investment is impressive, the sector needs to drive "efficiency improvements to achieve better returns and ultimately to drive greater affordability of its products", according to

  • Regeneron bags US approval for eczema drug Dupixent Regeneron bags US approval for eczema drug Dupixent

    Regeneron bags US approval for eczema drug Dupixent. Aims to balance affordability and rewarding innovation with the treatment's pricing. ... The companies have set the annual price of their drug at around $37, 000 per patient per year – which they

  • NICE agrees £20m cost ceiling for new drugs NICE agrees £20m cost ceiling for new drugs

    Sarah Woolnough, executive director of policy and information at Cancer Research UK, said the move to introduce an "affordability test" was unacceptable, and that cancer patients could die as a result

More from news
Approximately 2 fully matching, plus 82 partially matching documents found.

Latest Intelligence

  • Health on instalment Health on instalment

    Even cutting prices by half - an unlikely event in a land as keen on commerce as the US - would still leave such treatments well outside the affordability of commercial payers.

  • Working with our healthcare system more closely is vital Working with our healthcare system more closely is vital

    We know and recognise that the NHS must manage affordability, increasing the need to provide stable and predictable evaluations and outcomes for all parties.

  • The tipping point The tipping point

    Their increasing number and potential to tackle the affordability challenge is bringing biosimilars centre stage. ... Put simply, biosimilars enable innovation at a time when the mismatch between the rate of drug discovery and affordability has never

  • The real-world data conundrum The real-world data conundrum

    Thus, there are ongoing issues with and conversations about - not limited to developing countries - pricing and affordability of drugs.

  • Macron, Merkel and May: implications of the 2017 elections for the life science industry Macron, Merkel and May: implications of the 2017 elections for the life science industry

    The trend towards introducing additional affordability barriers can also be seen in the UK. ... In April 2017, NICE and NHS England introduced affordability measures to manage the uptake of innovative treatments, including a £20m budget impact threshold

More from intelligence
Approximately 0 fully matching, plus 26 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics